Emma Plested
Programme and Regulatory Affairs Director (UK)
Emma Plested is a Programme and Regulatory Affairs Director (UK) for the Oxford Vaccine Group (OVG). Emma joined the group in January 2005 and is responsible for the oversight of the full UK portfolio of trials undertaken by OVG. Emma leads the Trial and Project Management teams who are responsible for ensuring all trials and projects are delivered on time, within budget and in compliance with regulatory requirements.
Recent publications
Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in Communities.
Journal article
El Safadi D. et al, (2025), J Infect Dis, 231, e17 - e27
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.
Journal article
Feng S. et al, (2025), J Infect, 90
The Impact of Infant Bacille Calmette-Guérin Vaccination on the Immunogenicity of Other Vaccines: A Randomized Exploratory Study.
Journal article
Maytum A. et al, (2024), Pediatr Infect Dis J, 43, 809 - 812
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents.
Journal article
Ratcliffe H. et al, (2023), iScience, 26
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
Journal article
Kelly E. et al, (2023), J Infect, 87, 230 - 241